Catalyst overview
Research summary
This catalyst tracks a Phase 2 data readout for Budoprutug in Kidney disease, Primary Membranous Nephropathy. The expected timing is based on the latest available company guidance and may change.
10/15/24 Additional promising Ph1b data, full data at ASN '24 on 10/24.04/07/26:- Fast Track; PrisMN Ph2 data H2 2026. 05/05/26:- pMN Ph2 low-dose B-cell/anti-PLA2R data expected Q4 2026. SC Ph1 HV topline reported. 05/14/26:- Orphan Drug Designation noted for pMN; Ph2 data timing remains Q4 2026. 05/26/26:- PrisMN Ph2 trial-in-progress poster to be presented at ERA June 4-5, 2026. 08/06/26:- PrisMN enrollment reached 600 mg cohort; initial low-dose data expected Q4 2026.
Verification
Confirm timing and program details against the company announcement or filing.